Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial - Alexander C. Ford, Alexandra Wright-Hughes, Sarah L. Alderson, Pei-Loo Ow, Matthew J. Ridd, Robbie Foy, Gina Bianco, Felicity L. Bishop, Matthew Chaddock, Heather Cook, Deborah Cooper, Catherine Fernandez, Elspeth A. Guthrie, Suzanne Hartley, Amy Herbert - Dissemin

Language
Login

Published in

Elsevier, The Lancet, 2023

DOI: 10.1016/s0140-6736(23)01523-4

Links

Tools

Export citation

Search in Google Scholar

Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal article published in 2023 by Alexander C. Ford, Alexandra Wright-Hughes, Sarah L. Alderson, Pei-Loo Ow, Matthew J. Ridd, Robbie Foy, Gina Bianco, Felicity L. Bishop, Matthew Chaddock, Heather Cook, Deborah Cooper, Catherine Fernandez, Elspeth A. Guthrie, Suzanne Hartley, Amy Herbert and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO